Skip to main content

Day: January 25, 2021

PRESS RELEASE: NACON: Q3 2020/21 Sales: 48.7 M€, + 20.3%

                                                                                             Press release          Lesquin, 25 January 2021 17:45hrsQ3 2020/21 Sales: 48.7 M€, + 20.3%·Gaming Accessories : 32.5 M€, + 59%·Games Back catalogue : 6.9 M€, + 216%·Confirmation of annual targets       (1) Non audited data    (2) Mobile and Audio salesFurther strong growth in Q3 2020/21: +20.3%In Q3 2020/21 (1 October to 31 December 2020), Nacon posted 48.7 M€ sales up 20.3%, driven by the performance of RIG® headsets and increased back catalogue sales.GAMESDue to Q3 publishing releases limited to just two new games targetting profitable but narrow niches (Monster Truck®, Handball 21), sales were down by 19.7%.The share of digital sales grew further to represent 74.4% of quarterly sales.The contribution of the back catalogue (3), a source of high...

Continue reading

COMMUNIQUE DE PRESSE: NACON: Chiffre d’Affaires du 3ème trimestre 2020/21 : 48,7 M€, + 20,3%

                                                                                             Communiqué de presse          Lesquin, 25 janvier 2021 17h45Chiffre d’Affaires du 3ème trimestre 2020/21 : 48,7 M€, + 20,3%·Accessoires Gaming : 32,5 M€, + 59%·Back catalogue jeux : 6,9 M€, + 216%                  ·Confirmation des objectifs annuels       (1) Données non auditées    (2) Chiffres d’affaires Mobile et AudioPoursuite de la forte croissance au 3ème trimestre 2020/21 : + 20,3%Au 3ème trimestre 2020/21 (du 1er octobre au 31 décembre 2020), Nacon affiche un chiffre d’affaires de48,7 M€, en hausse de 20,3%, porté par la performance des casques RIG® et la hausse des ventes du back catalogue(3).JEUXEn raison d’une actualité éditoriale au 3ème trimestre uniquement portée par deux nouveaux jeux ciblant des niches rentables mais étroites (Monster...

Continue reading

Lumibird: 2020 Full-Year Revenues in Line With Expectations at €126.7m

Lannion, January 25, 2021 – 5:45pm2020 full-year revenues in line with expectations at €126.7m on a reported basis (+14.4% YoY and +40.7% in Q4) and €100m like-for-like (-9.7% YoY and +2.1% in Q4)The LUMIBIRD Group, the European leader for laser technologies, is reporting full-year revenues of €126.7m on a reported basis, up 14.4%. The fourth quarter was marked by record revenues of close to €50m, reflecting the return to organic growth (+2.1%) and the contribution from new activities (€13.2m).In the crisis context that affected 2020, full-year organic growth is down -9.7% or approximately -€10.7m, primarily factoring in the reduced level of activity on the MegaJoule contract (-€5.5m) for Photonics1and the drop in sales linked to the cancellation of major global shows (-€3.2m) for the Medical business.With better visibility concerning...

Continue reading

LUMIBIRD : CHIFFRE D’AFFAIRES ANNUEL 2020 EN LIGNE AVEC LES ATTENTES A 126,7 M€

Lannion, le 25/01/2021 – 17h45chiffre d’affaires annuel 2020 en ligne avec les attentes a 126,7 M€ en donnees publiees (+14,4% YoY et +40,7% au T4) / 100 M€ a perimètre constant (-9,7% YOY et +2,1% au T4)Le Groupe LUMIBIRD, leader européen des technologies laser, enregistre un chiffre d’affaires annuel de 126,7 M€ en données publiées en croissance de 14,4%. Le quatrième trimestre est marqué par un chiffre d’affaires record de près de 50 M€, reflétant le retour de la croissance organique (+2,1%) ainsi que la contribution des nouvelles activités (13,2 M€).Dans le contexte de crise qui a marqué l’exercice 2020, la croissance organique annuelle reste en retrait, à -9,7% soit environ -10,7 M€ qui s’expliquent principalement, en Photonique1par la diminution d’activité sur le contrat MégaJoule (-5,5 M€) et en Medical par le recul des ventes...

Continue reading

ASMI Share Buyback Update January 18 – 22, 2021

Almere, The NetherlandsJanuary 25, 2021, 5:45 p.m. CETASM International N.V. (Euronext Amsterdam: ASM) reports the following transactions, conducted under ASMI’s current share buyback program.These repurchases were made as part of the €100 million share buyback program announced on June 2, 2020. Of the total program, 75.2% has been repurchased. For further details including individual transaction information please visit: www.asm.com/investors/share-information/share-buyback.About ASM InternationalASM International NV, headquartered in Almere, the Netherlands, its subsidiaries and participations design and manufacture equipment and materials used to produce semiconductor devices. ASM International, its subsidiaries and participations provide production solutions for wafer processing (Front-end segment) as well as for assembly &...

Continue reading

BUREAU VERITAS : Bilan semestriel du contrat de liquidité au 31 décembre 2020

Communiqué de presseNeuilly-sur-Seine, France – 25 janvier 2021Bilan semestriel du contrat de liquiditéAu titre du contrat de liquidité confié par la société BUREAU VERITAS à EXANE BNP PARIBAS, en date de dénouement du 31 décembre 2020, les moyens suivants figuraient au compte de liquidité :138 398 titres BUREAU VERITAS5 874 605 eurosAu cours du 2nd semestre 2020, il a été négocié un total de :Achat : 1 679 138 titres (3 870 transactions) pour un total de 33 387 076 eurosVente : 1 804 001 titres (4 665 transactions) pour un total de 36 039 316 eurosIl est rappelé que :Lors du dernier bilan semestriel, en date de dénouement au 30 juin 2020, les moyens suivants figuraient au compte de liquidité :278 261 titres BUREAU VERITAS2 893 295 eurosAu cours du 1er semestre 2020, il a été négocié un total de :Achat : 2 150 645 (5 126 transactions)...

Continue reading

Eurobio Scientific: EXCEPTIONAL 2020 TURNOVER OF € 189 MILLION (+ 220%)

EXCEPTIONAL 2020 TURNOVER OF € 189 MILLION (+ 220%)•    A leading player in diagnostics able to adapt and meet the needs generated by the health crisis•    Strong momentum in traditional activities (+ 22% to € 71.9 million)•    Acceleration of the growth strategy thanks to improved visibility and greatly increased financial resourcesParis, January 25, 2021 – 5:45 p.m.Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro medical diagnostics and life sciences, today presents its consolidated annual turnover as of December 31, 2020.Exceptional growth of + 220% to € 189mEurobio Scientific recorded exceptional sales of € 188.9 million for the 2020 financial year, an increase of 220% compared to the previous financial year. More than 60% of these sales (€ 117m) are related to COVID-19 diagnostic...

Continue reading

Eurobio Scientific : CHIFFRE D’AFFAIRES 2020 EXCEPTIONNEL DE 189 M€ (+220%)

CHIFFRE D’AFFAIRES 2020 EXCEPTIONNEL DE 189 M€ (+220%)Un acteur leader du diagnostic capable de s’adapter pour répondre aux besoins générés par la crise sanitaireForte dynamique des activités traditionnelles (+22% à 71,9 M€)Accélération de la stratégie de croissance grâce à la visibilité et aux moyens financiers fortement accrusParis, le 25 janvier 2021 – 17h45Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro et les sciences de la vie, présente aujourd’hui son chiffre d’affaires annuel consolidé au 31 décembre 2020.Croissance exceptionnelle de +220% à 189 M€Eurobio Scientific enregistre pour l’exercice 2020 un chiffre d’affaires exceptionnel de 188,9 M€, soit une progression de 220% par rapport à l’exercice précédent. Plus de 60% de ces ventes (117 M€) sont liées aux...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.